Theriva Biologics Inc (TOVX)

[BooDog]

Innovation in Microbiome Research to Prevent C. diff, Antimicrobial Resistance and Improve GI Health

Upcoming Events




Digestive Disease Week (DDW 2017)

May 6–May 9, 2017

Chicago, IL

May 7, 2017

Poster Su2012: Poster Su2012: Increased pulmonary CO2 Excretion in Patients with Small Intestinal Bacterial Overgrowth (SIBO): Possible Implications for COPD
Session Number 7245 from 12:00 p.m. – 2:00 p.m. CDT
Venue: McCormick Place, South Hall

Poster Su1562: Initial paradoxical peaks on breath testing (first sample high) do not affect the diagnostic utility of the spot-methane breath test
Session Number 7130 from 12:00 p.m. – 2:00 p.m. CDT
Venue: McCormick Place, South Hall

Lecture 332g: An Orally Delivered Beta-Lactamase Protects the Gut Microbiome from Antibiotic-Mediated Damage and Mitigates the Propagation of Antibiotic-Resistance Genes in a Porcine Dysbiosis Model.
Session Number 3505 from 2:15 p.m. – 2:30 p.m. CDT
Venue: McCormick Place, room S503

May 9, 2017

Lecture 874j: SYN-004 (ribaxamase), an Oral ß-Lactamase, Prevented Clostridium difficile Infection and Protected Patients from Colonization by Antimicrobial Resistant Pathogens by Preserving Gut Microbiome Diversity in a Phase 2b Clinical Trial
Session Number 5235 from 10:30 a.m. – 10:45 a.m. CDT
Venue: McCormick Place, room S103



Association for Professionals in Infection Control and Epidemiology (APIC 2017)

June 14–June 17, 2017

Portland, OR



Microbiome Drug Development Summit

June 28–June 29, 2017

Boston, MA
=================================================

Yesterdays conference call

https://www.webcaster4.com/Webcast/Page/1096/20882

Slide show...
https://www.sec.gov/Archives/edgar/data/894158/000114420417024525/v465954_ex99-1.htm


Possibly there's already a transcript out.

Snagging a partnership is still possible but I didn't get the vibe that he has one in the net yet. In fact he mentioned Japan and other potential sources including a couple large investors (private placement?) and of course would not rule out a raise.
Burn rate will drop dramatically in the mean time since they're done with the ribaxamase trial. So I'm thinking a little patience through the conferences in June to see what happens.

The CDC likes what they see. So do I. Just a matter of patience and seeing how the stock holds up in the short term.

$SYN